Please login to the form below

Not currently logged in
Email:
Password:

Merck melanoma drug approved

The US Food and Drug Administration has granted marketing approval to Merck's Sylatron (peginterferon alfa-2b) melanoma treatment

The US Food and Drug Administration (FDA) has granted marketing approval to Merck's Sylatron (peginterferon alfa-2b) melanoma treatment.

The drug, which is injected subcutaneously, is indicated for the adjuvant treatment of node-positive melanoma. Specifically, it has been cleared for use within 84 days of definitive surgical resection including complete lymphadenectomy for the treatment of melanoma with microscopic or gross nodal involvement. Patients can self-inject the drug once a week, Merck noted.

The approval was based on a single, open-label trial of 1,256 patients who had had surgery and were randomised to receive either Sylatron or observation for five years.

The primary efficacy endpoint was relapse-free survival, which had an estimated median time of 34.8 months in the treatment group and 25.5 months in the observation-only group. There was no difference in overall survival between the Sylatron and the observation arms.

The drug was developed by Schering-Plough and became part of Merck's pipeline when the two companies merged.

Sylatron is the second significant new drug for melanoma to win FDA approval in recent weeks. Last month, the FDA approved Bristol-Myers Squibb's Yervoy (ipilimumab) for the treatment of unresectable or metastatic melanoma, noting that the therapy demonstrates a 'significant improvement' in overall survival for patients whose skin cancer cannot be treated with surgery or has spread to other organs.

12th April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...